XOMA (XOMA) Misses Q1 EPS by 3c

XOMA (NASDAQ: XOMA) reported Q1 EPS of ($0.19), $0.03 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $2.65 million versus the consensus estimate of $4.31 million.

2015 Guidance

The Company expects to spend approximately $60 million to $65 million in cash for ongoing operating activities during 2015. The Company's principal expenditures are costs associated with its gevokizumab Phase 3 clinical programs. The guidance assumes license and contract-related revenue to be received during the course of the year.

For earnings history and earnings-related data on XOMA (XOMA) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c